Cargando…
Megestrol acetate for cachexia–anorexia syndrome. A systematic review
In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. The mechanism by which MA increases appetite is unknown, and its effectiveness for anorexia and...
Autores principales: | Ruiz‐García, Vicente, López‐Briz, Eduardo, Carbonell‐Sanchis, Rafael, Bort‐Martí, Sylvia, Gonzálvez‐Perales, José Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989756/ https://www.ncbi.nlm.nih.gov/pubmed/29542279 http://dx.doi.org/10.1002/jcsm.12292 |
Ejemplares similares
-
Megestrol acetate in cachexia and anorexia
por: Yeh, Shing-shing, et al.
Publicado: (2006) -
Safety of Megestrol Acetate in Palliating Anorexia-Cachexia Syndrome in Patients with Castration-Resistant Prostate Cancer
por: Hong, Sungwoo, et al.
Publicado: (2013) -
A Systematic Review and Meta-Analysis of the Clinical Use of Megestrol Acetate for Cancer-Related Anorexia/Cachexia
por: Lim, Yu Liang, et al.
Publicado: (2022) -
Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer.
por: Gebbia, V., et al.
Publicado: (1996) -
A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients.
por: McMillan, D. C., et al.
Publicado: (1997)